Previous 10 | Next 10 |
Of all the new science coming in through ASH 2019, one of the most important abstracts is this one from Roche (RHHBY). Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Recept...
All subjects successfully self-administered a mini dose of RTU glucagon Rebound hypoglycemia observed more frequently in the placebo arm and with oral glucose tablet use Subcutaneous RTU glucagon is safe and well-tolerated Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specia...
Xeris Pharmaceuticals (NASDAQ: XERS ) is up 5% in decent post-holiday volume after disclosing that Chairman/CEO Paul Edick bought 17,935 shares this week. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
MAA submitted to EMA of liquid stable glucagon for severe hypoglycemia GVOKE ™ PFS launch underway GVOKE HypoPen ™ expected to launch July 2020 CHI program shifts to Expanded Access HAAF program discontinued based on Phase 2 results CHICAGO, Nov. 21...
Xeris Pharmaceuticals (NASDAQ: XERS ): Q3 GAAP EPS of -$1.22 beats by $0.02 . More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Gvoke™ (glucagon injection) pre-filled syringe (PFS) - now available by prescription MAA for ready-to-use glucagon on track for submission to EMA by year-end Data from three Phase 2 studies expected by year-end CHICAGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceut...
The European advisory group CHMP has adopted a positive opinion recommending approval of Eli Lilly's (NYSE: LLY ) Baqsimi (glucagon) for severe hypoglycemia (low blood sugar). More news on: Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Zealand Pharma A/S, Healthcare stocks news, ...
CHICAGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, has appointed Mark Thierer to...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it began dosing patients in a Phase 2 clinical study to ev...
The FDA approves Xeris Pharmaceuticals' ( XERS +0.9% ) GVOKE (glucagon), a ready-to-use, room temperature-stable liquid glucagon for the treatment of severe hypoglycemia (low blood sugar) in diabetics at least two years old. It will be available in prefilled syringe and autoinjector (Hyp...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...